Skip to main content

Human Immunodeficiency Virus 1 (HIV-1) PhenoSense® (Monogram® Phenotype)

CPT 87903; 87904(x12)
Synonyms
  • HIV-1 Resistance Testing
  • Phenotyping

Test Details

Methodology

Polymerase chain reaction (PCR) amplification and viral culture. PhenoSense® is a trademark of Monogram Biosciences®.

Result Turnaround Time

16 - 22 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Use

Determines viral phenotype resistance to three classes of commonly prescribed antiretroviral drugs: nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitors (PI). Viral replication capacity is also included.

Limitations

This procedure should be used for patients with documented HIV-1 infection and viral loads ≥500 copies/mL.

References

Baxter JD, Mayers DL, Wentworth DN, et al. CPCRA 046 Study Team. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, 1999. Abstract LB8.
Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999; 282(12):1135-1141. 10501116
Cohen C, Hunt S, Sension M, et al. Phenotypic resistance testing significantly improves response to therapy (Tx): A randomized trial (VIRA3001). Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif: 2000. Abstract 237.
Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial. Lancet. 1999; 353(9171):2195-2199. Erratum: Lancet. 1999; 354(9184):1128. 10392984
Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999; 282(12):1142-1149. 10501117
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Washington, DC: Department of Health and Human Services. January 28, 2000. Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

Specimen Requirements

Specimen

Plasma, frozen

Volume

3 mL

Container

Lavender-top (EDTA) or plasma preparation tube (PPT™)

Collection Instructions

Collect specimen in two lavender-top (EDTA) tubes or two PPT™ tubes. Do not use green-top (heparin) tubes. Centrifuge specimen within six hours of collection. Transfer plasma to one or more polypropylene screw-capped tube(s) (not "pop-top" tube or "snap-cap"), and freeze. Ship specimen frozen. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.

Storage Instructions

Freeze

Causes for Rejection

PPT™ not centrifuged; quantity not sufficient for analysis; heparinized plasma; nonfrozen specimen; specimen exposed to repeated freeze/thaw cycles; specimen received in “pop-top” or “snap-cap” tube

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
551800 PhenoSense(R) 551503 PhenoSense(R) PDF 45182-3
551800 PhenoSense(R) 551801 PhenoSense(R) 49665-3
551800 PhenoSense(R) 551504 PhenoSense(R) Interpretation 48767-8
Order Code551800
Order Code NamePhenoSense(R)
Order Loinc
Result Code551503
Result Code NamePhenoSense(R) PDF
UofM
Result LOINC45182-3
Order Code551800
Order Code NamePhenoSense(R)
Order Loinc
Result Code551801
Result Code NamePhenoSense(R)
UofM
Result LOINC49665-3
Order Code551800
Order Code NamePhenoSense(R)
Order Loinc
Result Code551504
Result Code NamePhenoSense(R) Interpretation
UofM
Result LOINC48767-8